Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 8, 2004, Pages 1448-1453

  Ouguerram, Khadija ^a,c   Chetiveaux, Maud ^a,c   Zair, Yassine ^a,c   Costet, Philippe ^a,c   Abifadel, Marianne ^b,c   Varret, Mathilde ^b,c   Boileau, Catherine ^b,c   Magot, Thierry ^a,c   Krempf, Michel ^a,c  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Apolipoprotein B100; Hypercholesterolemia; Kinetic analysis; Modeling; PCSK9

Indexed keywords

APOLIPOPROTEIN B100; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MUTANT PROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CATABOLISM; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; LIPID DEGRADATION; LIPID TRANSPORT; MALE; PRIORITY JOURNAL;

ADULT; AMINO ACID SUBSTITUTION; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHOLESTEROL ESTERS; FEMALE; GENES, DOMINANT; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; LIPOPROTEINS; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIVER; MALE; MIDDLE AGED; MUTATION, MISSENSE; POINT MUTATION; SERINE ENDOPEPTIDASES;

EID: 3943090528     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000133684.77013.88     Document Type: Article

References (38)

1. Leiper JM, Bayliss JD, Pease RJ, Brett DJ, Scott J, Shoulders CC. Microsomal triglyceride transfer protein, the aβlipoproteinemia gene product, mediates the secretion of apolipoprotein B-containing lipoproteins from heterologous cells. J Biol Chem. 1994;269: 21951-21954.
2. Sniderman A, Shapiro S, Marpola D, Skinner B, Tang B, Kwiterovich PO. Association of coronary atherosclerosis with hyperapoβlipoproteinemia. Proc Natl Acad Sci U S A. 1980;77:604-608.
3. James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux JP, Tacquet A, Demant T, Clegg RJ, Munro A, Oliver MF, Packard CJ, Shepherd J, Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res. 1989;30:159-169.
4. Gaffney D, Forster L, Castlake MJ, Bedford D, Stewart JP, Stewart G, Wieringa G, Dominiczak M, Miller JP, Packard CJ. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. Atherosclerosis. 2002;162:33-43.
5. Schuster H, Keller C, Wolfram G, Zölner N. Ten LDL receptor mutants explain one third of familial hypercholesterolemia in a germane sample. Arterioscler Thromb Vas. 1995;15:2176-2180.
6. Nora JJ, Lortscher RM, Sprangler RD, Bilheimer DW. Familial hypercholesterolemia with "normal" cholesterol in obligate heterozygotes. Am J Med Genet. 1985;22:585-591.
7. Bilheimer DW, East C, Grundy SM, Nora JJ. Clinical studies in a kindred with a kinetic LDL receptor mutation causing hypercholesterolemia. Am J Med Genet. 1985;22:593-598.
8. Zuliani G, Arca M, Signore A, Bader G, Fazio S, Chianelli M, Bellosta S, Compagna F, Montali A, Maioli M, Pacifico A, Ricci G, Fellin R. Characterisation of a new form of inherited hypercholesterolemia. Familial recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1999;19:802:809.
9. Arca M, Zuliani G, Wilund KR, Yi M, Campagna F, Fellin R, Calandra S, Ricci G, Clorioso N, Maioli M, Pintus P, Carra C, Cossu F, Cohen JC, Hobbs HH. Autosomal recessive hypercholesterolemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet. 2002;359:841-847.
10. Wilund KR, Yi M, Campagna F, Arca Marcello, Zuliani G, Fellin R, Ho YK, Hobbs HH, Cohen JC. Molecular mechanism of autosomal recessive hypercholesterolemia. Hum Mol Genet. 2002;11:3019-3030.
11. Varret M, Rabes JP, Saint-Jore B, Cenarro A, Marinoni JC, Civeira F, Devillers M, Krempf M, Coulon M, Thiart R, Kotze MJ, Schmidt H, Buzzi JC, Kostner GM, Bertolini S, Pocovi M, Rosa A, Farmer M, Martinez M, Junien C, Boileau C. Third major locus for autosomal dominant hypercholesterolemia maps to lp34.1-p32. Am J Hum Genet. 1999;64:1378-1387.
12. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
13. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci. 2003;100:928-933.
14. Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, Huang Y, Chiang LW, Grenier JM, Ozenberger BA, Jacobsen JS, Kennedy JD, DiStefano PS, Wood A, Bingham B. Characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys. 2003;420:55-67.
15. Bostrom K, Boren J, Wettesten M, Sjoberg A, Bondjers G, Wiklund O, Carlsson P, Olofsson SO. Studies on the assembly of apo B-100-containing lipoproteins in HepG2 cells. J Biol Chem. 1988;263:4434-4442.
16. Ouguerram K, Zaïr Y, Marchini JS, Charbonnel B, Magot T, Krempf M. Effect of atorvastatin on apoB100 containing lipoprotein metabolism using stable isotopes. J Pharmacol Exp Ther. 2003;306:332-337.
17. -Maugeais C, Ouguerram K, Frenais R, Maugère P, Charbonnel B, Magot T, Krempf M. Effect of LDL apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab. 2001;86:1679-1686.
18. Gaw A, Packard CJ, Shepherd J. Lipoprotein turnover and metabolism. In: Converse CA, Skinner ER, ed. Lipoprotein analysis. A practical approach. New York: Oxford University Press; 1992:128-133.
19. Havel RJ, Heder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
20. Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope trace data: link with radioactive kinetic formalism. Am J Physiol. 1992;262:E968-E975.
21. Chetiveaux M, Nazih H, Ferchaud-Roucher V, Lambert G, Zair Y, Masson M, Ouguerram K, Bouhours D, Krempf M. The differential apoA-I enrichment of preβ1 and αHDL is detectable by gel filtration separation. J Lipid Res. 2002;43:1986-1993.
22. Beghin L, Duhal N, Poulain P, Hauw P, Lacroix B, Lecerf JM, Bonte JP, Fruchart JC, Luc G. Measurement of apoB concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry. J Lipid Res. 2000;41:1172-1176.
23. Pont F, Duvillard L, Verges B, Gambert P. Development of compartmental models in stable isotope experiments. Application to lipid metabolism. Arterioscler Thromb Vasc Biol. 1998;18:853-860.
24. Maugeais C, Ouguerram K, Krempf M, Magot T. Kinetic study of apo B100 containing lipoprotein metabolism using amino acids labeled with stable isotopes: methodological aspects. Clin Chem Lab Med. 1998;36:739-745.
25. Pietzsch J, Wiedemann B, Julius U, Nitzsche S, Guhrisch S, Bergmann S, Leonhardt W, Jaross W, Hanefeld M. Increased clearance of LDL precursors in patients with heterozygous familial defective apo B100: A stable isotope approach. J Lipid Res. 1996;37:2074-2087.
26. Zulewski H, Ninnis R, Miserez AR, Baumstark MW, Keller U, VLDL and IDL apolipoprotein B100 kinetics in familial hypercholesterolemia due to LDL receptor function or to a defective apolipoprotein B100. J Lipd Res. 1998;39:380-387.
27. Zhang Z, Cianflone K, Sniderman AD. Role of cholesterol mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship. Arterioscler Thromb Vasc Biol. 1999;19:743-752.
28. Kraft HG, Demosky SJ, Schumacher K, Brewer HB, Hoeg J. M. Regulation of LDL receptor, apoB, and apoE protein and mRNA in Hep G2 cells. DNA. Cell Biol. 1992;11:291-300.
29. Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PHR, Attie AD. The rôle of LDL receptor in apolipoprotein B secretion. J Clin Invest. 2000;105:521-532.
30. Funatsu T, Suzuki K, Gotto M, Arai Y, Yakuta H, Tanaka H, Yasuda S, Ida M, Nishijima S, Miyata K. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis. 2001;157:107-115.
31. Borchardt RA, Davis RA. Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion. J Biol Chem. 1987;262:16394-16402.
32. Lusis AJ, Taylor BA, Quon D, Zollman S, LeBoeuf RC. Genetic factors controlling structure and expression of apolipoproteins B and E in mice. J Biol Chem. 1987;262:7594-7604.
33. Pullinger CR, North JD, Teng BB, Rifici VA, Ronhild de Brito AE, Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J Lipid Res. 1989;30:1065-1077.
34. Dashti N, Williams DL, Alaupovic P. Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. J Lipid Res. 1989;30:1365-1373.
35. Kaptein A, Roodenburg L, Princen HM. Butyrate stimulates the secretion of apolipoprotein (apo) A-I and apo B100 by the human hepatoma cell line Hep G2. Induction of apo A-I mRNA with no change of apo B100 mRNA. Biochem J. 1991;278:557-564.
36. Nilsson-Ehle P, Garfinkel AS, Schotz MC, Lipolytic enzymes and plasma lipoproteins metabolism. Annu Rev Biochem. 1980;49:667-693.
37. Schreier L, Berg G, Zago V, Gonzalez AI, Wikinski R. Kinetics of in vitro lipolysis of human very low-density lipoprotein by lipoprotein lipase. Nutr Metab Cardiovasc Dis. 2002;12:13-28.
38. Marz W, Baumstark MW, Scharnagl H, Ruzicka V, Buxbaum S, Herwig J, Pohl T, Russ A, Schaaf L, Berg A, et al. Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. J Clin Invest. 1993;92:2922-2933.